PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 768
- Registration Number
- NCT00457691
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Phase 1
Completed
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00457743
- Locations
- 🇯🇵
Pfizer Investigational Site, Chuo-ku, Tokyo, Japan
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
Phase 2
Withdrawn
- Conditions
- Diabetic RetinopathyDiabetes Mellitus
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00457470
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 102
- Registration Number
- NCT00454649
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: PF-04360365Drug: Placebo
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00455000
- Locations
- 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom
Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
Terminated
- Conditions
- Cardiovascular DiseaseCerebrovascular Disorders
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2008-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26784
- Registration Number
- NCT00452842
- Locations
- 🇺🇸
Pfizer Investigational Site, Clearwater, Florida, United States
Phase 1 Clinical Trial of Varenicline in Chinese Healthy Smoking Volunteers
Phase 1
Completed
- Conditions
- Smoking
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00452894
- Locations
- 🇨🇳
Pfizer Investigational Site, Beijing, China
Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00446784
- Locations
- 🇺🇸
Pfizer Investigational Site, Ducansville, Pennsylvania, United States
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00447005
- Locations
- 🇯🇵
Pfizer Investigational Site, Kashiwa, Chiba, Japan
Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2011-08-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 550
- Registration Number
- NCT00445770
- Locations
- 🇯🇵
Pfizer Investigational Site, Toyama, Japan
© Copyright 2025. All Rights Reserved by MedPath